Avalo Therapeutics, Inc.
AVTXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeAvalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. At a $1.06B market cap, Avalo Therapeutics, Inc. ranks as a small-cap company within healthcare. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases.
Market Cap
$1.06B
Beta
0.79
P/E (TTM)
—
P/E (Fwd)
-7.19
EPS (TTM)
$-4.41
EPS (Fwd)
$-2.74
ROE
-36.3%
ROA
-18.5%
Cash
$400.3M
Total Debt
$242,000
Free CF
-$23.3M
52W Change
74.5%
Annual Financials
Cash vs Debt
Where AVTX stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, AVTX finished 13.68% above its 150-day moving average ($16.67) and 12.40% above its 200-day moving average ($16.86). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AVTX overbought or oversold?
At the September 2, 2026 close, AVTX's RSI(14) was 45.2, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $400.3M in cash and $242K in debt, AVTX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$23.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -36.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $18.1M (2022) to $59K (2025), a 100% decline worth watching.
With cash comfortably exceeding debt, AVTX has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Avalo Therapeutics, Inc.'s trajectory.